Cardiac Implants LLC is engaged in the development and clinical investigation of percutaneous transcatheter devices for the treatment of structural heart diseases. Our first product under development is a percutaneous complete ring annuloplasty device for the treatment of patients with tricuspid regurgitation. Our device is the only one of its kind designed to meet specifically the mechanical and functional endpoints of surgical ring annuloplasty, the clinical gold standard for surgical valve repair. Our technology overcomes the challenges of ring dehiscence and retention by using the body’s natural healing process to create strong bonds between our ring annuloplasty implant and the valve annulus, enabling safe, easy and effective annular reduction, stabilization and maintenance using a low profile complete ring implant. Our ring implant is designed to function like a flexible ring during the healing period and a semi-rigid ring during the long term chronic phase, and to preserve the basic valve geometry of the anatomy. We collaborate with leading surgeons, cardiologists, pathologists, engineers, and scientists around the globe for the purpose of improving patient outcomes and quality of life. Our corporate headquarters is in American Canyon, California, and our R&D and manufacturing faclities are located in Israel and California. All our products under development are investigational and for investigational use only and not approved for clinical use in any jurisdiction, including the US.